Staff Search

In the News: Meningitis FAQ’s

MCH Not affected by CDC Menningitis AlertOn October 6th New England Compounding Pharmacy (NECC), announced a recall of all of its products that were compounded at and distributed from its facility in Framingham, Massachusetts. One of those products (preservative-free methylprednisolone acetate) , produced in three lots, has been linked to a national meningitis outbreak. None of the NECC’s medication directly linked to the meningitis outbreak has ever been utilized here at MCH. Monadnock Community Hospital has an excellent track record of safety with our patients. Prior to the FDA alert, MCH proactively removed all products from use that came from New England Compounding Center.

MCH’s highest priority is the safety of our patients and we are fully and proactively engaged in this effort. Beyond those medications directly linked to cases of meningitis, the FDA, on October 15th, advised hospitals across the US to contact patients that receivedany injectable drug from the NECC produced after May 21st, 2012 to see if they have experienced any unusual symptoms or reactions. MCH patients who have received any of these injectable drugs from the NECC will be contacted and given specific instructions to assist us in gathering patient information as we assist the FDA in their data collection. To date, the FDA has not been able to confirm any additional cases of infection have been caused by NECC products beyond the original product directly linked to the meningitis outbreak. Again, the product linked to meningitis from the NECC has never been used here at MCH.

Download our Fungal Meningitis FAQs document (PDF)